Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Mereo BioPharma Group plc - Sponsored ADR (MREO : NSDQ)
 
 • Company Description   
Mereo BioPharma Group plc is a biopharmaceutical company focused on the development of therapeutics for rare diseases. The Company's rare disease product candidates, setrusumab for the treatment of osteogenesis imperfecta and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease. Mereo BioPharma Group plc is based in LONDON.

Number of Employees: 36

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.69 Daily Weekly Monthly
20 Day Moving Average: 3,079,580 shares
Shares Outstanding: 159.00 (millions)
Market Capitalization: $268.71 (millions)
Beta: 0.46
52 Week High: $5.02
52 Week Low: $1.58
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -39.21% -41.49%
12 Week -26.52% -38.19%
Year To Date -51.71% -54.78%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
ONE CAVENDISH PLACE FOURTH FLOOR
-
LONDON,X0 W1G0QF
GBR
ph: 44-33-3023-7300
fax: -
investors@mereobiopharma.com http://www.mereobiopharma.com
 
 • General Corporate Information   
Officers
Denise Scots-Knight - Chief Executive Officer and Director
Michael Wyzga - Chairman
Christine Fox - Chief Financial Officer
Jeremy Bender - Director
Anders Ekblom - Director

Peer Information
Mereo BioPharma Group plc - Sponsored ADR (CORR.)
Mereo BioPharma Group plc - Sponsored ADR (RSPI)
Mereo BioPharma Group plc - Sponsored ADR (CGXP)
Mereo BioPharma Group plc - Sponsored ADR (BGEN)
Mereo BioPharma Group plc - Sponsored ADR (GTBP)
Mereo BioPharma Group plc - Sponsored ADR (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 589492107
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/12/25
Share - Related Items
Shares Outstanding: 159.00
Most Recent Split Date: (:1)
Beta: 0.46
Market Capitalization: $268.71 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $0.02 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $0.00 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/12/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 4.47
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -100.00%
vs. Previous Quarter: -100.00%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -69.33
12/31/24 - -67.85
ROA
06/30/25 - -
03/31/25 - -57.27
12/31/24 - -54.54
Current Ratio
06/30/25 - -
03/31/25 - 8.92
12/31/24 - 5.40
Quick Ratio
06/30/25 - -
03/31/25 - 8.92
12/31/24 - 5.40
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - 0.38
12/31/24 - 0.39
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©